

## Special Issue

# Cardiac Electrophysiology and Pharmacology

### Message from the Guest Editors

Cardiac arrhythmia is a leading cause of morbidity and mortality; therefore, large efforts in cardiac research have gone into finding appropriate antiarrhythmic drugs in the past few decades. Classical antiarrhythmic therapy includes the application of several  $\text{Na}^{+}$ -,  $\text{K}^{+}$ -, and  $\text{Ca}^{2+}$ -channel blockers. However, the pharmacological interventions are still hampered because the compounds often exert lack of selectivity and/or proarrhythmic side-effects. A further important aspect of the unsatisfactory pharmacological treatments is the lack of sufficient knowledge of the underlying mechanisms in several diseases. Better understanding of cardiac electrophysiology, both in health and in disease, could improve the effectiveness of the pharmacological treatments and may decrease the proarrhythmic risk. This Special Issue is designed for those fields of cardiac electrophysiology, pathophysiology, and pharmacology that are critically important to improve the efficacy and safety of antiarrhythmic treatment.

### Guest Editors

Dr. Norbert Nagy

Department of Pharmacology and Pharmacotherapy, Albert Szent-Györgyi Medical School, University of Szeged, 6721 Szeged, Hungary

Dr. Norbert Jost

Department of Pharmacology and Pharmacotherapy, Albert Szent-Györgyi Medical School, University of Szeged, 6721 Szeged, Hungary

### Deadline for manuscript submissions

closed (30 September 2023)



## Pharmaceuticals

an Open Access Journal  
by MDPI

Impact Factor 4.8  
CiteScore 7.7  
Indexed in PubMed



[mdpi.com/si/135693](https://mdpi.com/si/135693)

*Pharmaceuticals*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[pharmaceuticals@mdpi.com](mailto:pharmaceuticals@mdpi.com)

[mdpi.com/journal/  
pharmaceuticals](https://mdpi.com/journal/pharmaceuticals)





# Pharmaceuticals

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.8  
CiteScore 7.7  
Indexed in PubMed



[mdpi.com/journal/  
pharmaceuticals](https://mdpi.com/journal/pharmaceuticals)



## About the Journal

### Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us. We hope to handle your contribution to *Pharmaceuticals* soon.

---

### Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Ciências, Universidade de Lisboa, Lisboa, Portugal

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)